Local advanced or metabolic breast cancer treatment with PD-1 axis and Taxas diagonal

摘要

1. Claim 1: a method of treating or delaying the spread of locally advanced or metabolic breast cancer in an individual, including the effective management of antibody positive persons combined with human PD-1 axis and steroids. Claim 40: a method of treating or delaying a person's locally advanced or metabolic breast cancer, which includes a dose method including a treatment cycle to treat the individual on the 1st and 15th day of each cycle, An antibody that binds to the human PD-1 axis at a dose of about 840 Mg on days 1, 8, and 15 of each cycle,Taxonomic animals with a dose of about 100 mg / m,Repeat every 28 days Requirement 85: a method of enhancing immune function in people with locally advanced or metabolic breast cancer, including a dose method including a treatment cycle, to treat individuals on the 1st and 15th day of each cycle, 1. The target country combined with human PD-1 axis at a dose of about 840 mg, and classified animals at a dose of about 100 mg / m2 at 1, 8 and 15 days of each cycle,Each cycle is repeated every 28 days. Requirement 99: the use of human PD-1 axis combination antagonists to treat or delay the development of a person's local advanced or metabolic breast cancer, which consists of human PD-1 axis combination antagonists and alternative acceptable drug carriers,Treatment includes the use of drugs, plus an ingredient that includes an alternative drug and an acceptable carrier. Requirement 118: consists of a target country combined with the PD-1 human body axis and a local advanced or metabolic breast cancer drug carrier that can be selected for treatment or delayed treatment of a person. Treatment includes the management of this component Combined with the second component,The second component includes an alternative tax and a drug acceptable carrier. Item 137: a drug package that includes protesters on the PD-1 axis and an optional acceptable drug carrier, There is also a specification, which includes a description of drug management, as well as a component, which includes a classification and a drug acceptable optional carrier to treat or delay the development of a person's locally advanced or metabolized breast cancer.